Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With Obesity

Part of paid clinical trials in Tempe, Arizona.

Sponsor
Novo Nordisk A/S
Study ID
NCT02870231
Phase
PHASE1
Status
Completed

Conditions

  • Metabolism and Nutrition Disorder
  • Obesity

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Not accepted

Interventions

  • NNC9204-0530 — DRUG
    Once-daily subcutaneous (s.c., under the skin) administration.
  • liraglutide — DRUG
    Once-daily subcutaneous (s.c., under the skin) administration.
  • placebo — DRUG
    Once-daily subcutaneous (s.c., under the skin) administration

Study Details

This trial is conducted in the United States of America. The aim of this trial is to investigate Safety, Tolerability, PK (the exposure of the trial drug in the body) and PD (the effect of the investigated drug on the body) for Multiple Doses of NNC9204-0530 in Combination with Liraglutide in Male and Female Subjects being Overweight or with Obesity

Key Dates

Start date
Aug 18, 2016
Status verified
Sep 2018
Primary completion
Sep 3, 2017
Completion
Sep 3, 2017

Study Design

Enrollment
187 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: NNC9204-0530 / Placebo and Liraglutide 1.8
  • Active Comparator: NNC9204-0530 /Placebo and Liraglutide 3.0

Primary Outcome Measure

Number of treatment emergent adverse events [ Time Frame: Day 1-112 ]

Locations (2)

FacilityCityStateZIPSite coordinators
Novo Nordisk Investigational SiteTempeArizona85283-
Novo Nordisk Investigational SiteLincolnNebraska68502-

Find similar trials in Tempe, AZ

By condition
Obesity / overweight
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Novo Nordisk Investigational Site· Tempe, AZNovo Nordisk Investigational Site· Lincoln, NE

Related Studies